Biomarkers: new biomarker for Sjögren's syndrome--time to treat patients (Q85943298)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24045708%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

title

Biomarkers: new biomarker for Sjögren's syndrome--time to treat patients (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24045708%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

1 reference

Frans G M Kroese

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24045708%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

Hendrika Bootsma

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24045708%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

publication date

17 September 2013

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24045708%20AND%20SRC:MED&resulttype=core&format=json

Nature Reviews Rheumatology

22 February 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24045708%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

volume

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24045708%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

issue

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24045708%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

page(s)

570-572

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24045708%20AND%20SRC:MED&resulttype=core&format=json

Topical and systemic medications for the treatment of primary Sjögren's syndrome.

22 February 2020

cites work

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.143

MxA as a clinically applicable biomarker for identifying systemic interferon type I in primary Sjogren's syndrome.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.143

EULAR Sjogren's Syndrome Patient Reported Index (ESSPRI): development of a consensus patient index for primary Sjogren's syndrome

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.143

EULAR Sjogren's syndrome disease activity index: development of a consensus systemic disease activity index for primary Sjogren's syndrome

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.143

EULAR Sjogren's Syndrome Disease Activity Index (ESSDAI) is sensitive to show efficacy of rituximab treatment in a randomised controlled trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.143

Predominantly proinflammatory cytokines decrease after B cell depletion therapy in patients with primary Sjogren's syndrome

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.143

The interferon signature in autoimmune diseases

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.143

Activation of IFN pathways and plasmacytoid dendritic cell recruitment in target organs of primary Sjögren's syndrome

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.143

Gene expression profiling of minor salivary glands clearly distinguishes primary Sjögren's syndrome patients from healthy control subjects.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.143